2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.
Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discusses the use of fusion magnetic resonance imaging (MRI) in prostate cancer with OncLive during the LUGPA Annual Meeting.
Fusion MRI is typically used for a second biopsy, in patients with prostate cancer who are on active surveillance, or patients who have had a negative biopsy in the past, but their PSA is still rising, Buffington says. The MRI helps target an area that may have been missed on a prior biopsy.
The images from the MRI are then fused with the images on the ultrasound, which allows urologists to better target and bioposy the area.
Related Content: